AstraZeneca is one step closer to acquiring Alexion Pharmaceuticals having been cleared by the US Federal Trade Commission after an antitrust review, the company stated.
The Cambridge, UK, pharmaceutical and biotechnology company said the US clearance follows competition clearances in Canada, Brazil, Russia, and other countries globally.
“Additional global regulatory clearances are pending, including but not limited to the UK, EU and Japan,” the company added.
The deal is valued at US$39 billion. AstraZeneca expects to close the acquisition in the third quarter.
AstraZeneca in December agreed to pay US$175 a share for the Boston pharmaceutical company, which is known for its focus on rare and ultra-rare disease. Alexion holders will own around 15% of AstraZeneca’s shares outstanding when the deal closes.
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
T-Mobile’s Acquisition of Ka’ena Corporation Receives FCC Approval
Apr 26, 2024 by
CPI
UK Regulator Announces Two New Senior Executive Appointments
Apr 26, 2024 by
CPI
Paramount Global and Skydance Media Near Merger Deal, Eyeing CEO Change
Apr 26, 2024 by
CPI
BHP Unveils £31bn Mining Megamerger Proposal with Anglo American
Apr 25, 2024 by
nhoch@pymnts.com
ByteDance Prefers Shutdown Over Sale of TikTok Amid US Ban Threats
Apr 25, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Economics of Criminal Antitrust
Apr 19, 2024 by
CPI
Navigating Economic Expert Work in Criminal Antitrust Litigation
Apr 19, 2024 by
CPI
The Increased Importance of Economics in Cartel Cases
Apr 19, 2024 by
CPI
A Law and Economics Analysis of the Antitrust Treatment of Physician Collective Price Agreements
Apr 19, 2024 by
CPI
Information Exchange In Criminal Antitrust Cases: How Economic Testimony Can Tip The Scales
Apr 19, 2024 by
CPI